Global Progressive Supranuclear Palsy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Progressive Supranuclear Palsy treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including AbbVie Inc, AC Immune, AlzProtect SAS, Aquinnah Pharmaceuticals, Asceneuron SA and others.
A Significant contribution to the Progressive Supranuclear Palsy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Progressive Supranuclear Palsy pipeline included 18 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Progressive Supranuclear Palsy condition and increased access to investments is encouraging growth of Progressive Supranuclear Palsy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Progressive Supranuclear Palsy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Progressive Supranuclear Palsy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Progressive Supranuclear Palsy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Progressive Supranuclear Palsy. Further, orphan drug status, fast track designation, grants awarded and other special status for Progressive Supranuclear Palsy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Progressive Supranuclear Palsy pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Progressive Supranuclear Palsy Pipeline candidates-
A Significant contribution to the Progressive Supranuclear Palsy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Progressive Supranuclear Palsy pipeline included 18 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Progressive Supranuclear Palsy condition and increased access to investments is encouraging growth of Progressive Supranuclear Palsy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Progressive Supranuclear Palsy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Progressive Supranuclear Palsy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Progressive Supranuclear Palsy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Progressive Supranuclear Palsy. Further, orphan drug status, fast track designation, grants awarded and other special status for Progressive Supranuclear Palsy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Progressive Supranuclear Palsy pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Progressive Supranuclear Palsy Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Progressive Supranuclear Palsy drugs
- Late phase: Phase 3 and in-approval Progressive Supranuclear Palsy drugs
- Company overview
- Snapshot
- Progressive Supranuclear Palsy therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Progressive Supranuclear Palsy- Disease Overview
2.2 Progressive Supranuclear Palsy- Pipeline Snapshot
2.3 Progressive Supranuclear Palsy- Pipeline Drugs by Phase
2.4 Progressive Supranuclear Palsy- Pipeline Drugs by Company
2.5 Progressive Supranuclear Palsy- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AbbVie Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.2 AC Immune Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.3 AlzProtect SAS Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.4 Aquinnah Pharmaceuticals Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.5 Asceneuron SA Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.6 Biogen Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.7 Cortice Biosciences Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.8 Declion Pharmaceuticals Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.9 Delta Crystallon BV Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.10 Intellect Neurosciences Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.11 K-Stemcell Co Ltd Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.12 Merck & Co Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.13 Prana Biotechnology Ltd Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.14 Prothena Corp Plc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.15 TAU BIO-LOGIC Corp Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.16 TauRx Therapeutics Ltd Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.17 UCB SA Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.18 Voyager Therapeutics Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Progressive Supranuclear Palsy- Phase 1 Drug Details
4.2 Progressive Supranuclear Palsy- Phase 1 Drug Overview
4.3 Progressive Supranuclear Palsy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Progressive Supranuclear Palsy- Phase 2 Drug Details
5.2 Progressive Supranuclear Palsy- Phase 2 Drug Overview
5.3 Progressive Supranuclear Palsy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Progressive Supranuclear Palsy- Phase 3 Drug Details
6.2 Progressive Supranuclear Palsy- Phase 3 Drug Overview
6.3 Progressive Supranuclear Palsy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Progressive Supranuclear Palsy- Pre-clinical Phase Drug Details
7.2 Progressive Supranuclear Palsy- Pre-clinical Phase Drug Overview
7.3 Progressive Supranuclear Palsy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Progressive Supranuclear Palsy- Disease Overview
2.2 Progressive Supranuclear Palsy- Pipeline Snapshot
2.3 Progressive Supranuclear Palsy- Pipeline Drugs by Phase
2.4 Progressive Supranuclear Palsy- Pipeline Drugs by Company
2.5 Progressive Supranuclear Palsy- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AbbVie Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.2 AC Immune Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.3 AlzProtect SAS Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.4 Aquinnah Pharmaceuticals Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.5 Asceneuron SA Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.6 Biogen Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.7 Cortice Biosciences Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.8 Declion Pharmaceuticals Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.9 Delta Crystallon BV Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.10 Intellect Neurosciences Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.11 K-Stemcell Co Ltd Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.12 Merck & Co Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.13 Prana Biotechnology Ltd Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.14 Prothena Corp Plc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.15 TAU BIO-LOGIC Corp Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.16 TauRx Therapeutics Ltd Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.17 UCB SA Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
3.18 Voyager Therapeutics Inc Progressive Supranuclear Palsy Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Progressive Supranuclear Palsy- Phase 1 Drug Details
4.2 Progressive Supranuclear Palsy- Phase 1 Drug Overview
4.3 Progressive Supranuclear Palsy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Progressive Supranuclear Palsy- Phase 2 Drug Details
5.2 Progressive Supranuclear Palsy- Phase 2 Drug Overview
5.3 Progressive Supranuclear Palsy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Progressive Supranuclear Palsy- Phase 3 Drug Details
6.2 Progressive Supranuclear Palsy- Phase 3 Drug Overview
6.3 Progressive Supranuclear Palsy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Progressive Supranuclear Palsy- Pre-clinical Phase Drug Details
7.2 Progressive Supranuclear Palsy- Pre-clinical Phase Drug Overview
7.3 Progressive Supranuclear Palsy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
